Mast cell leukemia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2], Sogand Goudarzi, MD [3]

Mast cell leukemia was first described in 1906 by G. Joachim. Mast cell leukemia may be classified into two categories based on prognosis. Based on the duration of symptoms, mast cell leukemia may be classified into either acute or chronic. Genes involved in the pathogenesis of mast cell leukemia include KIT D816V and non-KIT D816V. There are no characteristic findings of mast cell leukemia on gross pathology. On microscopic histopathological analysis, multifocal sheets and clusters of mast cells in bone marrow sections are findings of mast cell leukemia. Common causes of mast cell leukemia include genetic mutations. Common genetic mutations involved in the development of mast cell leukemia can be found here. Mast cell leukemia must be differentiated from other diseases such as systemic mastocytosis, myelomastocytic leukemia, hairy cell leukemia, reactive mast cell hyperplasia, and peripheral T-cell leukemia. The incidence of mast cell leukemia increases with age; the median age at diagnosis is 52 years. Mast cell leukemia commonly affects individuals between 5 to 76 years of age. Females are more commonly affected with mast cell leukemia than males. The female to male ratio is 1.5 to 1. Mast cell leukemia usually affects individuals of the Caucasian race. Risk factor for mast cell leukemia is systemic mastocytosis, a premalignant condition. Factors involved in malignant transformation of systemic mastocytosis into mast cell leukemia include advanced age, history of weight loss, anemia, thrombocytopenia, hypoalbuminemia, and an excess of bone marrow blasts. According to the United States Preventive Services Task Force, there is insufficient evidence to recommend routine screening for mast cell leukemia. If left untreated,patients with mast cell leukemia may progress to develop weight loss, ascites, and bone abnormalities. Common complications of mast cell leukemia include hepatosplenomegaly, lymphadenopathy, and osteoporosis. Prognosis is generally poor, and the median survival time is less than six months. Symptoms of mast cell leukemia include fever, weight loss, weakness, flushes, and pruritis. Common physical examination findings of mast cell leukemia include hepatosplenomegaly, lymphadenopathy, bone abnormalities, and ascites.Laboratory findings consistent with the diagnosis of mast cell leukemia include abnormal complete blood count, biochemistry, and immunohistochemistry. The mainstay of therapy for symptomatic mast cell leukemia patients is immunochemotherapy.

Mast cell leukemia was first described in 1906 by G. Joachim.^[1]

Mast cell leukemia may be classified into two categories based on prognosis.^[1] Based on the duration of symptoms, mast cell leukemia may be classified into either acute or chronic.^[2][3]

Genes involved in the pathogenesis of mast cell leukemia include KIT D816V and non-KIT D816V.^[1][4][5] There are no characteristic findings of mast cell leukemia on gross pathology.^[6] On microscopic histopathological analysis, multifocal sheets and clusters of mast cells in bone marrow sections are findings of mast cell leukemia.^[7]

Common causes of mast cell leukemia include genetic mutations. Common genetic mutations involved in the development of mast cell leukemia can be found here.^[1][4][5]

Mast cell leukemia must be differentiated from other diseases such as systemic mastocytosis, myelomastocytic leukemia, hairy cell leukemia, reactive mast cell hyperplasia, and peripheral T-cell leukemia.^[7][6]

The incidence of mast cell leukemia increases with age; the median age at diagnosis is 52 years.^[1] Mast cell leukemia commonly affects individuals between 5 to 76 years of age.^[1] Females are more commonly affected with mast cell leukemia than males. The female to male ratio is 1.50 to 1.^[1] Mast cell leukemia usually affects individuals of the Caucasian race.^[1]

Risk factor for mast cell leukemia is systemic mastocytosis, a premalignant condition. Factors involved in malignant transformation of systemic mastocytosis into mast cell leukemia include advanced age, history of weight loss, anemia, thrombocytopenia, hypoalbuminemia, and an excess of bone marrow blasts.^[1]

According to the United States Preventive Services Task Force, there is insufficient evidence to recommend routine screening for mast cell leukemia.^[8]

If left untreated, patients with mast cell leukemia may progress to develop weight loss, ascites, and bone abnormalities.^[4] Common complications of mast cell leukemia include hepatosplenomegaly, lymphadenopathy, and osteoporosis.^[4] Prognosis is generally poor, and the median survival time is less than six months.^[1]

Symptoms of mast cell leukemia include fever, weight loss, weakness, flushes, and pruritis.^[4]

Common physical examination findings of mast cell leukemia include hepatosplenomegaly, lymphadenopathy, bone abnormalities, and ascites.^[1][4]

Larboratoy findings consistent with the diagnosis of mast cell leukemia include abnormal complete blood count, biochemistry, and immunohistochemistry.^[1][4][9]

CT scan may be helpful in the diagnosis of mast cell leukemia. Findings on CT scan of the abdomen suggestive of mast cell leukemia include ascites, hepatosplenomegaly, and upper abdominal lymphadenopathy.^[10]

There are no MRI findings associated with mast cell leukemia.

There are no other imaging findings associated with mast cell leukemia.

Other diagnostic studies for mast cell leukemia include flow cytometry.^[9]

The mainstay of therapy for symptomatic mast cell leukemia patients is immunochemotherapy.^[1][4]

The predominant therapy for mast cell leukemia is immunochemotherapy. Surgical management, such as splenedctomy or bone marrow transplantation may be required in certain cases.^[1]

There are no primary or secondary preventive measures available for mast cell leukemia.

Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2],Sogand Goudarzi, MD [3]

Mast cell leukemia was first described in 1906 by G. Joachim.

Mast cell leukemia was first described in 1906 by G. Joachim.^[1]

Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2],Sogand Goudarzi, MD [3]

Mast cell leukemia may be classified into two categories based on prognosis to leukemic and aleukemic. Also, it can be classified to acute or chronic according to the duration of the symptoms.

• In 2016 the World Health Organization (WHO) changed classification of tumors of hematopoietic and lymphoid tissues.Based on the duration of symptoms, mast cell leukemia may be classified into either acute or chronic.^[1][2][3]
• In the current classification mastocytosis is a major category. In the last classification mastocytosis was subtype of major category (myeloproliferative neoplasms).^[2]

1.Cutaneous mastocytosis (CM)

2.Systemic mastocytosis

• Indolent systemic mastocytosis (ISM)
• Smoldering systemic mastocytosis (SSM)
• Systemic mastocytosis with an associated hematological neoplasm (SM-AHN)
• Aggressive systemic mastocytosis (ASM)
• Mast cell leukaemia (MCL)

3.Mast cell sarcoma (MCS)

• Mast cell leukemia may be classified into two categories based on prognosis:^[3]

• Leukemic variant

• Circulating mast cells ≥ 10%
• Bone marrow mast cells ≥ 20%

• Aleukemic variant

• Circulating mast cells < 10%

• Based on the duration of symptoms, mast cell leukemia may be classified into:^[1]

• Acute mast cell leukemia
• Chronic mast cell leukemia

Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2], Sogand Goudarzi, MD [3]

Genes involved in the pathogenesis of mast cell leukemia include KIT D816V and non-KIT D816V.^[1][2][3] There are no characteristic findings of mast cell leukemia on gross pathology.^[4] On microscopic histopathological analysis, multifocal sheets and clusters of mast cells in bone marrow sections are findings of mast cell leukemia.^[5]

• Mutation of KIT is a hallmark of the mast cell leukemia.
• Adult-type human mastocytosis is characterized by mutations in c-KIT at codon 816, which cause constitutive activation of KIT kinase.
• Different classes of activating KIT mutations respond differentially to KIT inhibitors depending on the site and type of mutation.
• D816V c-KIT mutation is the most frequent mutation, found in more than 80% of adult patients with systemic mastocytosis especially in the aggressive forms with a frequency of more than 95% in mast cell leukemia patients.^[1]
• Mutations in SRSF2, ASXL1 or RUNX1 are founded in mast cell leukemia patient.^[6]
• The majority patients with mast cell leukemai have signs of organ damage.^[6]

Genes involved in the pathogenesis of mast cell leukemia include:^[1][2][3]

• KIT D816V
• non-KIT D816V

Mast cell leukemia may be associated with systemic mastocytosis.^[2]

There are no characteristic findings of mast cell leukemia on gross pathology. Gross specimens are not seen typically.^[4]

On microscopic histopathological analysis, findings of mast cell leukemia include:^[5]

• Multifocal sheets of mast cells
• Clusters of mast cells

• 
  _{Peripheral blood showing mast cell leukemia.^[7]}

• Atypical mast cells express multiple surface antigens such as:^[1]

• CD117
• CD11c
• CD13
• CD29
• CD33
• CD44
• CD45
• CD63
• CD68
• CD71
• CD2
• CD22
• CD25
• CD54

• The role of these antigens is however not yet understood.
• CD2 and CD25 antigens are important markers.

• Their positivity on the surface of mast cells constitute minor criteria for the diagnosis of mast cell disease.

Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2], Sogand Goudarzi, MD [3]

Common causes of mast cell leukemia include genetic mutations. Common genetic mutations involved in the development of mast cell leukemia can be found here.^[1][2][3]

Common causes of mast cell leukemia include genetic mutations. Common genetic mutations involved in the development of mast cell leukemia can be found here.^[1][2][3]

Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2], Sogand Goudarzi, MD [3]

Mast cell leukemia must be differentiated from other diseases such as systemic mastocytosis, myelomastocytic leukemia, hairy cell leukemia, reactive mast cell hyperplasia, monocytoid B-cell lymphoma, and peripheral T-cell leukemia.

Mast cell leukemia must be differentiated from other diseases such as:^[1][2]

• Systemic mastocytosis
• Myelomastocytic leukemia
• Peripheral T-cell leukemia
• Reactive mast cell hyperplasia
• Hairy cell leukemia
• Monocytoid B-cell lymphoma
• Fibroblast proliferation

Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2], Sogand Goudarzi, MD [3]

The incidence of mast cell leukemia increases with age; the median age at diagnosis is 52 years.^[1] Mast cell leukemia commonly affects individuals between 5 to 76 years of age.^[1] Females are more commonly affected with mast cell leukemia than males. The female to male ratio is 1.50.^[1] Mast cell leukemia usually affects individuals of the Caucasian race.^[1]

Mast cell leukemia is a rare subtype which represents less than 2% of systemic mastocytosis.^[2]

The incidence of mast cell leukemia increases with age; the median age at diagnosis is 52 years.^[1]

Mast cell leukemia commonly affects individuals between 5 to 76 years of age.^[1]

Females are more commonly affected with mast cell leukemia than males. The female to male ratio is 1.50 to 1.^[1]

Mast cell leukemia usually affects individuals of the Caucasian race.^[1]

Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]

Risk factor for mast cell leukemia is systemic mastocytosis, a premalignant condition. Factors involved in malignant transformation of systemic mastocytosis into mast cell leukemia include advanced age, history of weight loss, anemia, thrombocytopenia, hypoalbuminemia, and an excess of bone marrow blasts.

• Risk factor for mast cell leukemia is systemic mastocytosis, a premalignant condition.
• Common risk factors in the development of malignant transformation of systemic mastocytosis into mast cell leukemia include:^[1]

• Advanced age
• History of weight loss
• Anemia
• Thrombocytopenia
• Hypoalbuminemia
• An excess of bone marrow blasts

Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]

According to the United States Preventive Services Task Force, there is insufficient evidence to recommend routine screening for mast cell leukemia.

According to the United States Preventive Services Task Force, there is insufficient evidence to recommend routine screening for mast cell leukemia.^[1]

Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]

If left untreated, patients with mast cell leukemia may progress to develop weight loss, ascites, and bone abnormalities.Common complications of mast cell leukemia include hepatosplenomegaly, lymphadenopathy, and osteoporosis.^[1] Prognosis is generally poor, and the median survival time is less than six months.^[2]

If left untreated, patients with mast cell leukemia may progress to develop weight loss, ascites, and bone abnormalities.Common complications of mast cell leukemia include hepatosplenomegaly, lymphadenopathy, and osteoporosis.^[1] Prognosis is generally poor, and the median survival time is less than six months.^[2]

Template:WH Template:WS